Biomimetic Matrix for Ex Vivo and In Vivo Activation of T Cells

用于 T 细胞离体和体内激活的仿生基质

基本信息

  • 批准号:
    10392463
  • 负责人:
  • 金额:
    $ 47.94万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2020
  • 资助国家:
    美国
  • 起止时间:
    2020-07-01 至 2024-03-31
  • 项目状态:
    已结题

项目摘要

PROJECT SUMMARY The objective of this study is to engineer an artificial T cell-stimulating matrix (aTM) that presents antigen-specific and cell-specific biochemical and biophysical cues to control phenotype and improve functional profiles of T cells in a biomimetic context that captures key biochemical and biophysical features of the lymph node (LN). LN provides the critical microenvironment that orchestrates the presentation format and dynamics of the antigen-specific signals in a precise and controlled manner that leads to T cell activation, expansion, and maturation. Currently available T cell stimulating matrices while carrying the antigen-presentation complexes and co-stimulating cues, however, lacks adequate supporting cues inherent to the T cell stimulating microenvironment in the LN. We will design and characterize an aTM that integrates the three key T-cell stimulating signals: antigen-specific (Signal 1), co-stimulatory (Signal 2), and cytokines (Signal 3), together with extracellular matrix (ECM) molecules and tunable biophysical properties inspired by the properties of both antigen-presenting cells (APCs) and the LN. We will test the hypothesis that co-presenting the APC signal cues in such a biomimetic context during T cell stimulation will result in functional T cells with controlled phenotypic profiles and potency. and mechanism revealing how all signaling cues synergize to active and polarize T cells. In Specific Aim 1, we will determine key matrix properties of the aTM that mediate robust CD8+ T cell activation using aTMs prepared from hyaluronic acid (HA) hydrogel and HA-nanofiber composite (NHC) matrix. In Specific Aim 2, we will define optimal signaling cues and their presentation configuration that influence CD4+ T cell activation and polarization on aTM; and demonstrate persistence and functions of aTM-stimulated and adoptively transferred antigen-specific CD4+ T cells. In Specific Aim 3, we will use aTM microparticles to co-stimulate CD8+ and CD4+ T cells and evaluate therapeutic benefits of a combination treatment with CD4+ and CD8+ T cells in a cancer immunotherapy mouse model. If successful, this study will result in the first set of engineered aTM that delivers robust stimulation of antigen-specific CD8+ and CD4+ T cells that promise improved therapeutic outcomes; and further enrich our understandings of design principles and mechanism of signaling cues in stimulation, polarization, and activation of T cells.
项目总结 这项研究的目的是设计一种人工T细胞刺激基质(ATM),它呈现抗原特异性 和细胞特异的生化和生物物理线索来控制T细胞的表型和改善其功能 仿生背景,捕捉淋巴(LN)的关键生化和生物物理特征。LN提供了 关键微环境,协调抗原特异信号的呈现格式和动态 精确和可控的方式,导致T细胞的激活、扩增和成熟。当前可用的T细胞 然而,在携带抗原呈递复合体和共刺激线索的同时刺激基质,缺乏 LN中T细胞刺激微环境所固有的足够支持线索。我们将设计和 描述集成了三个关键T细胞刺激信号的ATM的特征:抗原特异性(信号1)、共刺激 (信号2)和细胞因子(信号3),以及细胞外基质(ECM)分子和可调生物物理 由抗原提呈细胞(APC)和LN的特性启发而来的特性。我们将检验这一假设 在T细胞刺激期间在这样的仿生环境中共同呈现APC信号提示将导致功能性 具有受控表型和效力的T细胞。以及揭示所有信号信号如何协同作用的机制 活化和极化T细胞。在具体目标1中,我们将确定ATM的关键矩阵属性 透明质酸水凝胶和透明质酸纳米纤维复合材料制备的ATM对CD8+T细胞的激活作用 矩阵。在具体目标2中,我们将定义影响最佳信令提示及其呈现配置 在ATM上的CD4+T细胞的激活和极化;并展示了ATM刺激的和 过继转移的抗原特异性CD4+T细胞。在特定的目标3中,我们将使用ATM微粒来协同刺激 CD_8~+和CD_4~+T细胞及其联合治疗的疗效 一种肿瘤免疫治疗的小鼠模型。如果成功,这项研究将产生第一套工程化ATM 提供强大的抗原特异性CD8+和CD4+T细胞的刺激,承诺改善治疗结果; 进一步丰富了我们对刺激、极化等信号传递线索的设计原理和机制的理解 和T细胞的激活。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Hai-Quan Mao其他文献

Hai-Quan Mao的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Hai-Quan Mao', 18)}}的其他基金

A nanofiber-hydrogel composite plug for perianal fistula repair
用于肛周瘘修复的纳米纤维-水凝胶复合塞
  • 批准号:
    10607324
  • 财政年份:
    2023
  • 资助金额:
    $ 47.94万
  • 项目类别:
Biomimetic Matrix for Ex Vivo and In Vivo Activation of T Cells
用于 T 细胞离体和体内激活的仿生基质
  • 批准号:
    10608176
  • 财政年份:
    2020
  • 资助金额:
    $ 47.94万
  • 项目类别:
Biomimetic Matrix for Ex Vivo and In Vivo Activation of T Cells
用于 T 细胞离体和体内激活的仿生基质
  • 批准号:
    10205064
  • 财政年份:
    2020
  • 资助金额:
    $ 47.94万
  • 项目类别:
Training and Dissemination
培训与传播
  • 批准号:
    10645135
  • 财政年份:
    2019
  • 资助金额:
    $ 47.94万
  • 项目类别:
Training and Dissemination
培训与传播
  • 批准号:
    10436874
  • 财政年份:
    2019
  • 资助金额:
    $ 47.94万
  • 项目类别:
Training and Dissemination
培训与传播
  • 批准号:
    9790440
  • 财政年份:
    2019
  • 资助金额:
    $ 47.94万
  • 项目类别:
Training and Dissemination
培训与传播
  • 批准号:
    10223296
  • 财政年份:
    2019
  • 资助金额:
    $ 47.94万
  • 项目类别:
Promote Organization and Integration of Regenerated Neurons from Transplanted Human Neural Stem Cells
促进移植的人类神经干细胞再生神经元的组织和整合
  • 批准号:
    9392271
  • 财政年份:
    2017
  • 资助金额:
    $ 47.94万
  • 项目类别:
Nanoparticle Delivery of DNA Vaccine Against Zika Virus
纳米颗粒递送抗寨卡病毒 DNA 疫苗
  • 批准号:
    9379639
  • 财政年份:
    2017
  • 资助金额:
    $ 47.94万
  • 项目类别:
Directed In Vivo Differentiation of Neural Stem Cells for Repair of Brain Lesion
神经干细胞体内定向分化修复脑损伤
  • 批准号:
    8824696
  • 财政年份:
    2014
  • 资助金额:
    $ 47.94万
  • 项目类别:

相似海外基金

Time to ATTAC: Adoptive Transfer of T cells Against gp100+ Cells to treat LAM
ATTAC 时间:针对 gp100 细胞的 T 细胞过继转移来治疗 LAM
  • 批准号:
    10682121
  • 财政年份:
    2023
  • 资助金额:
    $ 47.94万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10576370
  • 财政年份:
    2022
  • 资助金额:
    $ 47.94万
  • 项目类别:
Phase I clinical trial of adoptive transfer of autologous folate receptor-alpha redirected CAR T cells for ovarian cancer
自体叶酸受体-α重定向CAR T细胞过继转移治疗卵巢癌的I期临床试验
  • 批准号:
    10387023
  • 财政年份:
    2022
  • 资助金额:
    $ 47.94万
  • 项目类别:
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10248409
  • 财政年份:
    2019
  • 资助金额:
    $ 47.94万
  • 项目类别:
A phase I clinical study of adoptive transfer of regulatory T cells (Tregs) and low-dose interleukin-2 (IL-2) for the treatment of chronic graft-versus-host disease (GVHD): gene-marking to inform rational combination therapy
调节性 T 细胞 (Treg) 和低剂量白细胞介素 2 (IL-2) 过继转移治疗慢性移植物抗宿主病 (GVHD) 的 I 期临床研究:基因标记为合理的联合治疗提供信息
  • 批准号:
    nhmrc : GNT1163111
  • 财政年份:
    2019
  • 资助金额:
    $ 47.94万
  • 项目类别:
    Project Grants
Determining mechanisms of enhanced antitumor efficacy of four-day expanded Th17 cells for adoptive transfer
确定用于过继转移的四天扩增 Th17 细胞增强抗肿瘤功效的机制
  • 批准号:
    10462684
  • 财政年份:
    2019
  • 资助金额:
    $ 47.94万
  • 项目类别:
Gene edited lymphoid progenitors for adoptive transfer as a treatment of primary immunodeficiency
基因编辑的淋巴祖细胞用于过继转移作为原发性免疫缺陷的治疗
  • 批准号:
    398018062
  • 财政年份:
    2018
  • 资助金额:
    $ 47.94万
  • 项目类别:
    Research Grants
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9308643
  • 财政年份:
    2017
  • 资助金额:
    $ 47.94万
  • 项目类别:
Overcoming immune suppression in cancer by targeting PSGL-1 in T cells used for adoptive transfer
通过靶向用于过继转移的 T 细胞中的 PSGL-1 克服癌症中的免疫抑制
  • 批准号:
    9447149
  • 财政年份:
    2017
  • 资助金额:
    $ 47.94万
  • 项目类别:
Targeting Cancer miRNAs by Adoptive Transfer of Programmed B Lymphocytes
通过程序化 B 淋巴细胞的过继转移靶向癌症 miRNA
  • 批准号:
    8893915
  • 财政年份:
    2014
  • 资助金额:
    $ 47.94万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了